Unacceptability of the reference price It is necessary to abandon the reference price for patent-protected products, which is particularly harmful because it negatively impacts quality and equity, constitutes a strong deterrent to investment in R&D and the introduction of innovative medicines . Reduction of the tax burden on the sector The tax burden on the sector is on average 65%, a value that creates a strong imbalance compared to other countries. It is necessary to lighten it in its components, including the total deductibility of expenses for conferences and congresses, on which companies have re-launched their commitment with the definition of new and even more rigorous self-regulation rules. Intensification of public-private partnerships Italy has many public and private Centers of Excellence, an international specialization in biomedical research and industrial capabilities to translate it into innovative products. Alignment of bureaucratic obligations with European best practices Work still needs to be done to speed up administrative obligations, optimizing procedures, giving companies certainty of deadlines. ICP dated 28/05/2008 NUM 4_APRIL 2008 p. 13
